7 results on '"Corino, Alessandra"'
Search Results
2. Comparison among populations with severe and intermediate alpha1-antitrypsin deficiency and chronic obstructive pulmonary disease.
- Author
-
PILONI, Davide, OTTAVIANI, Stefania, SADERI, Laura, CORDA, Luciano, BADERNA, Paolo, BARZON, Valentina, BALDERACCHI, Alice M., SEEBACHER, Christine, BALBI, Bruno, ALBICINI, Federica, CORINO, Alessandra, MENNITTI, Maria C., TIRELLI, Claudio, SPREAFICO, Fabio, BOSIO, Matteo, MARIANI, Francesca, SOTGIU, Giovanni, CORSICO, Angelo G., and FERRAROTTI, Ilaria
- Published
- 2024
- Full Text
- View/download PDF
3. Comprehensive Clinical Diagnostic Pipelines Reveal New Variants in Alpha-1 Antitrypsin Deficiency.
- Author
-
Ottaviani, Stefania, Bartoli, Giulia, Carroll, Tomas P., Gangemi, Fabrizio, Balderacchi, Alice M., Barzon, Valentina, Corino, Alessandra, Piloni, Davide, McElvaney, Noel G., Corsico, Angelo G., Irving, James A., Fra, Annamaria, and Ferrarotti, Ilaria
- Subjects
TRYPSIN inhibitors ,GENETIC variation ,MISSENSE mutation ,PULMONARY emphysema ,DISEASE progression - Abstract
Alpha-1 antitrypsin deficiency (AATD) is an underdiagnosed disorder associated with mutations in the SERPINA1 gene encoding alpha-1 antitrypsin (AAT). Severe AATD can manifest as pulmonary emphysema and progressive liver disease. Besides the most common pathogenic variants S (E264V) and Z (E342K), many rarer genetic variants of AAT have been found in patients and in the general population. Here we report a panel of new SERPINA1 variants, including 4 null and 16 missense alleles, identified among a cohort of individuals with suspected AATD whose phenotypic follow-up showed inconclusive or atypical results. Because the pathogenic significance of the missense variants was unclear purely on the basis of clinical data, the integration of computational, biochemical, and cellular studies was used to define the associated risk of disease. Established pathogenicity predictors and structural analysis identified a panel of candidate damaging mutations that were characterized by expression in mammalian cell models. Polymer formation, intracellular accumulation, and secretory efficiency were evaluated experimentally. Our results identified two AAT mutants with a Z-like polymerogenic severe deficiency profile (S
milano and Mcampolongo ) and three milder variants (Xsarezzo , Pdublin, and Ctiberias ). Overall, the experimentally determined behavior of the variants was in agreement with the pathogenicity scores of the REVEL (an ensemble method for predicting the pathogenicity of rare missense variants) predictor, supporting the utility of this bioinformatic tool in the initial assessment of newly identified amino acid substitutions of AAT. Our study, in addition to describing 20 new SERPINA1 variants, provides a model for a multidisciplinary approach to classification of rare AAT variants and their clinical impact on individuals with rare AATD genotypes. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
4. Improving the Laboratory Diagnosis of M-like Variants Related to Alpha1-Antitrypsin Deficiency.
- Author
-
Barzon, Valentina, Ottaviani, Stefania, Balderacchi, Alice Maria, Corino, Alessandra, Piloni, Davide, Accordino, Giulia, Coretti, Manuela, Mariani, Francesca, Corsico, Angelo Guido, and Ferrarotti, Ilaria
- Subjects
CLINICAL pathology ,ISOELECTRIC focusing ,LUNG diseases ,PROTEASE inhibitors ,GENETIC mutation - Abstract
Alpha1-antitrypsin (AAT) is a serine protease inhibitor that is encoded by the highly polymorphic SERPINA1 gene. Mutations in this gene can lead to AAT deficiency (AATD), which is associated with an increased risk of lung and/or liver disease. On the basis of electrophoretic migration, AAT variants are named with capital letters; M (medium) signifies the normal protein. Among pathological variants, the M-like ones represent a heterogeneous group of rare allelic variants that exhibit the same electrophoretic pattern as the M wild-type protein, which makes them difficult to detect with routine methods. In order to avoid their misdiagnosis, the present study defines and validates effective methods for the detection of two pathogenic M-like variants, M
wurzburg and Mwhitstable . Comparison of protein phenotypes using isoelectric focusing of samples that presented the Mwurzburg variant, as revealed by exons 5 sequencing, identified a particular electrophoretic pattern amenable to the Mwurzburg protein. The specific phenotyping pattern was retrospectively validated, thus enabling the detection of 16 patients with Mwurzburg variant among the subjects already tested but not sequenced according to our diagnostic algorithm. The Mwhitstable allele was detected by intron 4 sequencing of SERPINA1 gene. Mwurzburg and Mwhitstable are often misdiagnosed and the introduction of diagnostic improvements can help the clinical management, especially in patients with established lung disease without any other reported risk factors. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
5. Comparison of different algorithms in laboratory diagnosis of alpha1-antitrypsin deficiency.
- Author
-
Balderacchi, Alice M., Barzon, Valentina, Ottaviani, Stefania, Corino, Alessandra, Zorzetto, Michele, Wencker, Marion, Corsico, Angelo G., and Ferrarotti, Ilaria
- Subjects
CLINICAL pathology ,MEDICAL personnel ,ALGORITHMS ,MEDICAL care ,GENETIC disorders ,LUNGS - Abstract
Alpha1-antitrypsin deficiency (AATD) is an inherited condition that predisposes individuals to an increased risk of developing lung and liver disease. Even though AATD is one of the most widespread inherited diseases in Caucasian populations, only a minority of affected individuals has been detected. Whereas methods have been validated for AATD testing, there is no universally-established algorithm for the detection and diagnosis of the disorder. In order to compare different methods for diagnosing AATD, we carried out a systematic review of the literature on AATD diagnostic algorithms. Complete biochemical and molecular analyses of 5,352 samples processed in our laboratory were retrospectively studied using each of the selected algorithms. When applying the diagnostic algorithms to the same samples, the frequency of False Negatives varied from 1.94 to 12.9%, the frequency of True Negatives was 62.91% for each algorithm and the frequency of True Positives ranged from 24.19 to 35.15%. We, therefore, highlighted some differences among Negative Predictive Values, ranging from 0.83 to 0.97. Accordingly, the sensitivity of each algorithm ranged between 0.61 and 0.95. We also postulated 1.108 g/L as optimal AAT cut-off value, in absence of inflammatory status, which points to the possible presence of genetic AATD. The choice of the diagnostic algorithm has a significant impact on the correct diagnosis of AATD, which is essential for appropriate treatment and medical care. The fairly large number of possible false negative diagnoses revealed by the present paper should also warn clinicians of negative results in patients with clinically-suspected AATD. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Erratum: Stella, G.M. et al. Brain Metastases from Lung Cancer: Is MET an Actionable Target? Cancers 2019, 11, 271.
- Author
-
Stella, Giulia M., Corino, Alessandra, Berzero, Giulia, Kolling, Stefan, Filippi, Andrea R., and Benvenuti, Silvia
- Subjects
- *
BRAIN tumors , *LUNG tumors , *METASTASIS - Published
- 2019
- Full Text
- View/download PDF
7. Brain Metastases from Lung Cancer: Is MET an Actionable Target?
- Author
-
Stella, Giulia M., Corino, Alessandra, Berzero, Giulia, Kolling, Stefan, Filippi, Andrea R., and Benvenuti, Silvia
- Subjects
- *
BRAIN tumor treatment , *TREATMENT of lung tumors , *BRAIN tumors , *CYTOKINES , *GENETICS , *METASTASIS , *LUNG tumors , *ONCOGENES , *TUMOR classification , *DISEASE progression , *DISEASE complications , *DIAGNOSIS ,BRAIN tumor diagnosis ,BRAIN tumor genetics - Abstract
The process of metastatic dissemination begins when malignant cells start to migrate and leave the primary mass. It is now known that neoplastic progression is associated with a combination of genetic and epigenetic events. Cancer is a genetic disease and this pathogenic concept is the basis for a new classification of tumours, based precisely on the presence of definite genetic lesions to which the clones are addicted. Regarding the scatter factor receptors MET and Recepteur d'Origin Nantais (RON), it is recognised that MET is an oncogene necessary for a narrow subset of tumours (MET-addicted) while it works as an adjuvant metastogene for many others. This notion highlights that the anti-MET therapy can be effective as the first line of intervention in only a few MET-addicted cases, while it is certainly more relevant to block MET in cases of advanced neoplasia that exploit the activation of the invasive growth program to promote dissemination in other body parts. Few data are instead related to the role played by RON, a receptor homologous to MET. We have already demonstrated an implication of MET and RON genes in brain metastases from lung cancer. On this basis, the aim of this work is to recapitulate and dissect the molecular basis of metastatic brain dissemination from lung cancer. The latter is among the big killers and frequently gives rise to brain metastases, most often discovered at diagnosis. Molecular mechanisms leading to tumour spread to the brain are mostly unknown and in turn these tragic cases are still lacking effective therapies. Based on previously published data from our group, we aim to summarise and analyse the pathogenic mechanisms leading to activation of the scatter factor receptor in brain metastatic lesions of lung primaries, from the point of view of replacing the currently used empirical treatment with a more targeted approach. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.